DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery (AQNA-DY002)
Primary Purpose
Mature Cataracts
Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
DYME
DYME
Sponsored by
About this trial
This is an interventional treatment trial for Mature Cataracts
Eligibility Criteria
Inclusion Criteria:
- Have a cataract sufficiently opaque/mature/brunescent that, in the surgeon's assessment,a dye could facilitate surgery;
- Be aged at least 18 years old at the time of enrollment;
- Be in a medical condition suitable for cataract surgery;
- Able and willing to participate in study examinations and visit schedule; and
- Understand and freely consent to participate in the study.
Exclusion Criteria:
- In either eye, ocular infection or inflammation within the past 3 months;
- Known allergy to BBG 250;
- Uncontrolled intercurrent diseases including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia;
- Active treatment for cancer or systemic infection within the past month;
- Active treatment with systemic corticosteroids within the past month;
- Previous participation in this Study for the contralateral eye;
- Participation in another clinical trial involving an investigational therapeutic during the past 30 days or 5.5 half-lives (if applicable), whichever is longer;
- Unwillingness to participate in the study or inability to give informed consent; or
- Any medical condition that in the opinion of the Investigator may compromise the research subject's safety or ability to participate in the study.
Sites / Locations
- Peace Laser Eye Center
- Center for Excellence in Eye Care
- Ophthalmology Consultants, Ltd.
- Silverstein Eye Centers
- St. John's Clinic Eye Specialists
- Ballas Surgery Center
- Brar-Parekh Eye Associates
- Island Eye Surgicenter
- Eye Care Specialists
- LV Prasad Eye Institute
- Narayana Nethralaya
- Bhagwan Mahaveer Jain Hospital
- Narayana Nethralaya
- Bombay City Eye Institute & Research Centre
- Sankara Nethralaya
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
High Dose
Low Dose
Arm Description
Outcomes
Primary Outcome Measures
Optimal curvilinear capsulorrhexis with a single dose, as assessed by the surgeon based on the tissue dyed and subsequently removed.
Uncomplicated discharge
Secondary Outcome Measures
Quality of stain
Intra-ocular safety of DYME as measured by best corrected visual acuity, corneal endothelial cell count, intraocular pressure, presence/absence of retained dye, duration of surgery, and the absence of dye related adverse events
Intra-ocular safety of DYME as measured by corneal endothelial cell count
Full Information
NCT ID
NCT00596492
First Posted
January 9, 2008
Last Updated
February 27, 2009
Sponsor
Aqumen Biopharmaceuticals, N.A.
1. Study Identification
Unique Protocol Identification Number
NCT00596492
Brief Title
DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery
Acronym
AQNA-DY002
Official Title
AQNA-DY002: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Terminated
Why Stopped
Terminated due to reasons unrelated to safety
Study Start Date
May 2008 (undefined)
Primary Completion Date
September 2008 (Anticipated)
Study Completion Date
December 2008 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Aqumen Biopharmaceuticals, N.A.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to test the hypothesis that DYME is safe and effective as a drug to facilitate continuous curvilinear capsulorhexis (CCC) by selectively staining the anterior capsule. Secondary objectives are to compare the safety and effectiveness of DYME to that of a smaller dose of the same API.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mature Cataracts
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
High Dose
Arm Type
Active Comparator
Arm Title
Low Dose
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
DYME
Intervention Description
2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
Intervention Type
Drug
Intervention Name(s)
DYME
Intervention Description
2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
Primary Outcome Measure Information:
Title
Optimal curvilinear capsulorrhexis with a single dose, as assessed by the surgeon based on the tissue dyed and subsequently removed.
Time Frame
During surgery
Title
Uncomplicated discharge
Time Frame
Three months post-op
Secondary Outcome Measure Information:
Title
Quality of stain
Time Frame
during surgery
Title
Intra-ocular safety of DYME as measured by best corrected visual acuity, corneal endothelial cell count, intraocular pressure, presence/absence of retained dye, duration of surgery, and the absence of dye related adverse events
Time Frame
1-day and 1-week post-op
Title
Intra-ocular safety of DYME as measured by corneal endothelial cell count
Time Frame
Three months post-op
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have a cataract sufficiently opaque/mature/brunescent that, in the surgeon's assessment,a dye could facilitate surgery;
Be aged at least 18 years old at the time of enrollment;
Be in a medical condition suitable for cataract surgery;
Able and willing to participate in study examinations and visit schedule; and
Understand and freely consent to participate in the study.
Exclusion Criteria:
In either eye, ocular infection or inflammation within the past 3 months;
Known allergy to BBG 250;
Uncontrolled intercurrent diseases including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia;
Active treatment for cancer or systemic infection within the past month;
Active treatment with systemic corticosteroids within the past month;
Previous participation in this Study for the contralateral eye;
Participation in another clinical trial involving an investigational therapeutic during the past 30 days or 5.5 half-lives (if applicable), whichever is longer;
Unwillingness to participate in the study or inability to give informed consent; or
Any medical condition that in the opinion of the Investigator may compromise the research subject's safety or ability to participate in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hardy Kagimoto, M.D.
Organizational Affiliation
Aqumen Biopharmaceuticals, N.A.
Official's Role
Study Director
Facility Information:
Facility Name
Peace Laser Eye Center
City
Inglewood
State/Province
California
ZIP/Postal Code
90301
Country
United States
Facility Name
Center for Excellence in Eye Care
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Ophthalmology Consultants, Ltd.
City
Des Peres
State/Province
Missouri
ZIP/Postal Code
63131
Country
United States
Facility Name
Silverstein Eye Centers
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64133
Country
United States
Facility Name
St. John's Clinic Eye Specialists
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65804
Country
United States
Facility Name
Ballas Surgery Center
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Brar-Parekh Eye Associates
City
West Paterson
State/Province
New Jersey
ZIP/Postal Code
07424
Country
United States
Facility Name
Island Eye Surgicenter
City
Carle Place
State/Province
New York
ZIP/Postal Code
11514
Country
United States
Facility Name
Eye Care Specialists
City
Kingston
State/Province
Pennsylvania
ZIP/Postal Code
18704
Country
United States
Facility Name
LV Prasad Eye Institute
City
Hyderabaad
State/Province
Andhra Pradesh
ZIP/Postal Code
500034
Country
India
Facility Name
Narayana Nethralaya
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560020
Country
India
Facility Name
Bhagwan Mahaveer Jain Hospital
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560052
Country
India
Facility Name
Narayana Nethralaya
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560099
Country
India
Facility Name
Bombay City Eye Institute & Research Centre
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400 007
Country
India
Facility Name
Sankara Nethralaya
City
Chennai
State/Province
Tamilnadu
ZIP/Postal Code
600006
Country
India
12. IPD Sharing Statement
Learn more about this trial
DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery
We'll reach out to this number within 24 hrs